Helmy M. Siragy

Primary Appointment

  • Professor, Medicine- Endocrinology and Metabolism

Contact

Research Interest(s)

Biology and Pathophysiology of Angiotensin Receptor Subtypes in the Kidney and Heart Diseases

Research Description

Dr. Helmy M. Siragy developed the microdialysis technique, which led to a golden Age of revolutionary discoveries about the nature of angiotensin receptors and renal paracrine hormones. The lab focuses on the biology and pathophysiology of angiotensin subtype receptors in cardiovascular system. Currently the lab is conducting pioneering translational research that has major clinical impact and is related to cardiac ischemia, diabetic kidney disease, local tissue production of aldosterone and its paracrine functions in kidney and heart.

Our Lab is also involved in clinical studies related to aldosterone pulse activity in normal individuals and in patients with primary aldosteronism, vasopressin receptors in kidney and management of hyponatremia, and one of our ongoing studies investigating the effects of long term angiotensin subtype 1 receptor blockade on cardiovascular morbidity and mortality.

Selected Publications

  • Matavelli L, Huang J, Siragy H. In vivo regulation of renal expression of (pro)renin receptor by a low-sodium diet. American journal of physiology. Renal physiology. 2012;303(12): F1652-7. PMID: 23077099 | PMCID: PMC3532474
  • Matavelli L, Siragy H. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. Journal of cardiovascular pharmacology. 2012;61(1): 17-22. PMID: 23011470 | PMCID: PMC3538933
  • Waeber B, Siragy H. Mild hypertension: to treat or not to treat? Current hypertension reports. 2012;15(1): 1-2. PMID: 23152161
  • A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vascular health and risk management. 2011;7 297-313. PMID: 21633727 | PMCID: PMC3104607
  • Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2011;25(1): 87-97. PMID: 21213120
  • To ACCELERATE hypertension control. Current hypertension reports. 2011;13(4): 259-61. PMID: 21494776
  • Abadir P, Walston J, Carey R, Siragy H. Angiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFα production. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2011;31(6): 471-4. PMID: 21288138 | PMCID: PMC3104285
  • Huang J, Matavelli L, Siragy H. Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade. Clinical and experimental pharmacology & physiology. 2011;38(4): 215-21. PMID: 21265872 | PMCID: PMC3077929
  • Huang J, Siragy H. Sodium depletion enhances renal expression of (pro)renin receptor via cyclic GMP-protein kinase G signaling pathway. Hypertension. 2011;59(2): 317-23. PMID: 22203739 | PMCID: PMC3266459
  • Matavelli L, Huang J, Siragy H. Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. Journal of cardiovascular pharmacology. 2011;59(3): 281-7. PMID: 22075749 | PMCID: PMC3296909